Evaluation of Maintenance Capecitabine Therapy After First-Line Chemotherapy in Metastatic Pancreatic Cancer.

Q2 Medicine

Asian Pacific Journal of Cancer Prevention Pub Date : 2026-09-01 DOI:10.31557/APJCP.2026.27.9.3203

Mohamed Abouelfetouh Shehata, Alshimaa Mahmoud Alhanafy, Mohamed Elsherbini Hassan, Nahla Atef Shaaban, Amira Hosny Hegazy

{"title":"Evaluation of Maintenance Capecitabine Therapy After First-Line Chemotherapy in Metastatic Pancreatic Cancer.","authors":"Mohamed Abouelfetouh Shehata, Alshimaa Mahmoud Alhanafy, Mohamed Elsherbini Hassan, Nahla Atef Shaaban, Amira Hosny Hegazy","doi":"10.31557/APJCP.2026.27.9.3203","DOIUrl":null,"url":null,"abstract":"Objective: To assess the clinical impact of maintenance capecitabine following first-line modified FOLFIRINOX in patients with metastatic pancreatic cancer (mPC), focusing on progression-free survival (PFS), overall survival (OS), quality of life (QoL), and the toxicity profile.Methods: This phase II prospective trial, 60 patients with histologically confirmed stage IV pancreatic adenocarcinoma (ECOG PS ≤1, normal organ function, and measurable metastatic disease) who were enrolled after completing modified FOLFIRINOX. Participants were randomized into two groups: Arm A received maintenance capecitabine, and Arm B underwent observation only.Results: Baseline patient and disease characteristics were comparable between both groups. The pancreatic head was the predominant tumor site (73.3% in Arm A vs. 86.7% in Arm B). After six months of maintenance therapy, stable disease was reported in 33.3% of Arm A and 0% of Arm B. Toxicity levels were not significantly different. Patients in Arm B demonstrated earlier deterioration in QoL, with median time to decline of 3.2 months compared with 6.9 months in Arm A. Median PFS and OS favored the capecitabine arm (6.13 vs. 3.57 months and 14.20 vs. 10.97 months, respectively). Multivariate Cox regression confirmed treatment arm as the most independent prognostic factor influencing both PFS and OS.Conclusion: Maintenance capecitabine after first-line modified FOLFIRINOX in mPC was well tolerated and may enhance PFS and OS while maintaining an acceptable quality of life.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3203-3212"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2026.27.9.3203","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To assess the clinical impact of maintenance capecitabine following first-line modified FOLFIRINOX in patients with metastatic pancreatic cancer (mPC), focusing on progression-free survival (PFS), overall survival (OS), quality of life (QoL), and the toxicity profile.

Methods: This phase II prospective trial, 60 patients with histologically confirmed stage IV pancreatic adenocarcinoma (ECOG PS ≤1, normal organ function, and measurable metastatic disease) who were enrolled after completing modified FOLFIRINOX. Participants were randomized into two groups: Arm A received maintenance capecitabine, and Arm B underwent observation only.

Results: Baseline patient and disease characteristics were comparable between both groups. The pancreatic head was the predominant tumor site (73.3% in Arm A vs. 86.7% in Arm B). After six months of maintenance therapy, stable disease was reported in 33.3% of Arm A and 0% of Arm B. Toxicity levels were not significantly different. Patients in Arm B demonstrated earlier deterioration in QoL, with median time to decline of 3.2 months compared with 6.9 months in Arm A. Median PFS and OS favored the capecitabine arm (6.13 vs. 3.57 months and 14.20 vs. 10.97 months, respectively). Multivariate Cox regression confirmed treatment arm as the most independent prognostic factor influencing both PFS and OS.

Conclusion: Maintenance capecitabine after first-line modified FOLFIRINOX in mPC was well tolerated and may enhance PFS and OS while maintaining an acceptable quality of life.

查看原文本刊更多论文

转移性胰腺癌一线化疗后卡培他滨维持治疗的评价。

目的：评估卡培他滨在一线改良FOLFIRINOX治疗后对转移性胰腺癌（mPC）患者的临床影响，重点关注无进展生存期（PFS）、总生存期（OS）、生活质量（QoL）和毒性。方法：这项II期前瞻性试验，60例组织学证实的IV期胰腺腺癌（ECOG PS≤1，器官功能正常，可测量的转移性疾病）患者在完成改良FOLFIRINOX后入组。参与者被随机分为两组：A组接受维持性卡培他滨治疗，B组仅接受观察。结果：两组患者的基线和疾病特征具有可比性。胰头为主要肿瘤部位（A组73.3%，B组86.7%）。维持治疗6个月后，A组33.3%的患者病情稳定，b组0%的患者病情稳定，毒性水平无显著差异。B组患者表现出较早的生活质量恶化，平均下降时间为3.2个月，而a组为6.9个月。中位PFS和OS有利于卡培他滨组（分别为6.13个月对3.57个月和14.20个月对10.97个月）。多因素Cox回归证实，治疗组是影响PFS和OS最独立的预后因素。结论：mPC患者在一线改良FOLFIRINOX后维持卡培他滨耐受性良好，可提高PFS和OS，同时维持可接受的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.